Efficacy and visual prognostic factors of intravitreal bevacizumab as needed for macular edema secondary to central retinal vein occlusion
Miki Hirose, Wataru Matsumiya, Shigeru Honda, Makoto NakamuraDepartment of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Chuo-ku, Kobe, Hyogo, JapanPurpose: Our aim was to investigate the efficacy and prognostic factors of intraocular injections of bevacizumab as...
Guardado en:
Autores principales: | Hirose M, Matsumiya W, Honda S, Nakamura M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1e94c3c01fd4481caaf9e05cc0209c4a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
por: Juan Carlos Mesa Gutiérrez, et al.
Publicado: (2008) -
Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
por: Thapa R, et al.
Publicado: (2012) -
The comparison of intravitreal triamcinolone and bevacizumab in patients with macular edema secondary to branch retinal vein occlusion
por: Gokce G, et al.
Publicado: (2014) -
Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion
por: Udaondo P, et al.
Publicado: (2011) -
The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
por: Ivanovska Adjievska B, et al.
Publicado: (2017)